BPTS Biophytis SA

10.64
+0.44  (+4%)
Previous Close 10.2
Open 10.6
52 Week Low 10.2
52 Week High 18.5
Market Cap $121,071,294
Shares 11,378,881
Float 11,378,881
Enterprise Value $129,582,252
Volume 757
Av. Daily Volume 2,717
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Sarconeos (BIO101) - COVA
COVID-19
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Sarconeos (BIO101) - SARA-INT
Sarcopenia
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Macuneos (BIO201)
Dry Age-Related Macular Degeneration (AMD)
Phase 1
Phase 1
Phase 1 clinical trial to be initiated 2H 2021.
Sarconeos (BIO101) - MYODA
Duchenne Muscular Dystrophy
Phase 1
Phase 1
Phase 1 planned for 1H 2021 depending on COVID-19 situation.

Latest News

  1. PARIS and Cambridge, Mass., June 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces a new line of financing through Bonds Redeemable in Cash and New and Existing Shares (ORNANE) with Atlas, a specialized investment fund based in New York (United States), for €32 million (the "2021 Atlas Contract"). This line of financing will be used for further clinical…

    PARIS and Cambridge, Mass., June 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces a new line of financing through Bonds Redeemable in Cash and New and Existing Shares (ORNANE) with Atlas, a specialized investment fund based in New York (United States), for €32 million (the "2021 Atlas Contract"). This line of financing will be used for further clinical development of Sarconeos (BIO101) in sarcopenia following our SARA phase 2 results and for the next development steps of the product in COVID-19 following our COVA phase 2-3 results, as well as the financing of the Company's activities going forward.

    The Company also announces the issuance of 240 ORNANE Bonds, for a total amount of €6 million under its existing convertible bond agreement with Atlas (the "2020 Atlas Contract").

    Stanislas Veillet, President and CEO of Biophytis, said: "We are pleased to conclude this new ORNANE contract with Atlas that allows us to secure the Company's financing going forward. In the meantime, we have just drawn two tranches of convertible under the existing agreement with Atlas for a total of €6 million, that will enable Biophytis to i) source starting materials required for the coming production of registration and commercial batches – provided positive results from COVA, ii) to scale up manufacturing and industrialization activities and to iii) start the Expanded Access COVA Program. These activities are directly linked to the potential filing for Emergency Use Authorization in the U.S. and Conditional Marketing Authorisation in the EU later in 2021."

    a)  2021 Atlas Contract



    The new financing instrument allows the issuance of 1280 bonds with an option for exchange in cash and/or conversion into new or existing shares (ORNANE). Subject to the issue of the eighth and last tranche under the 2020 Atlas Contract, the €32 million total financing can be drawn by Biophytis over the next three years, without obligation, through 8 successive tranches of €4 million each. This facility will secure the Company cash position, in order to continue the development of its clinical activities in particular further development of Sarconeos (BIO101). The risks inherent in this financing scheme are described in the "Risk Factors" section of the Company's Annual 2020 Report available on BIOPHYTIS website (www.biophytis.com) and in the "Risk Factors" section of the Company's registration statement on Form F-1 and other reports filed with the Securities and Exchange Commission (the "SEC").

    Legal framework

    The issued securities will give Atlas access immediately or in the future to the Company's share capital with cancelation of the shareholders' preferential subscription rights to the benefit of a category of persons pursuant to Article L. 225-129 et seq. of the French Commercial Code.

    Pursuant to the delegation granted by the General Meeting of Shareholders of 10 May 2021, the Company's Board of Directors approved the conclusion of the 2021 Atlas Contract during its meeting on June 8, 2021. The 2021 Atlas Contract was concluded on 14 June 2021.

    This offer of financial securities did not result in a prospectus subject to AMF approval.

    The Company will keep the shareholders informed of the exercise of the ORNANE and the subsequent conversions, through a summary table of the ORNANE, and the number of shares in circulation, all of which will be available on the Company website.

    Main characteristics of the ORNANE

    The ORNANE will have a par value of €25 000 euros. They will not bear interest and will have a 24-month maturity from issuance. The holder of ORNANE may request at any time to convert them during their maturity period, and the Company shall have the right to redeem the ORNANE in cash. In case of cash redemption, the amount reimbursed will be limited to 110% of the principal.

    At the end of the maturity period, and in the case where the ORNANE would not have been redeemed either in cash or in new or existing shares, the holder will have the obligation to convert the ORNANE.

    The holder can ask to convert the ORNANE at any time at the conversion parity determined by the following formula: N = Vn / (R x P), where

    • "N" is the number of shares yielded by the conversion,
    • "Vn" is the par value of the ORNANEs, i.e., €25,000 each,
    • "R" is the conversion ratio, i.e., 1.00,
    • "P" is the conversion price, i.e., the Pricing Period VWAP during the Pricing Period of 10 trading days preceding the reception of the Conversion Notice

    On the day of the conversion request, the Company may redeem the ORNANE in cash using the following formula: V = (Vn/P) * Pr, where

    • "V" is the amount to be redeemed to the holder.
    • "Pr" is the revised price.

    The revised price is the lowest price between (i) the volume weighted average price over the 10 trading days preceding the date on which conversion is requested and (ii) P*1.10

    ORNANE may be transferred by their holders only to Affiliates and will not be subject to a request for trading admission on the Euronext Growth market.

    Number of securities and dilution (assumptions)

    Based on the 113 854 795 outstanding shares, and based on issuance and conversion of a €4 million tranche, and of all tranches on 14 June 2021 and a conversion price equal to €0,9376, the impact on a shareholder's 1% stake in the Company's capital prior to the operation would be:

    Impact on a shareholder's 1% stake in the Company's capital prior to the transactionNon dilutedDiluted
       
    Before issuing of new ORNANE1.00%0.95%
         
    Upon conversion of one tranche of the new 2021 ORNANE contract from Atlas: issuing of 4 266 197 additional shares0.96%0.92%
         
    Upon conversion of the totality of the new 2021 ORNANE contract from Atlas: issuing of 34 129 576 additional shares0.77%0.74%

    b)  Drawing of 2 tranches of the 2020 Atlas Contract

    On April 7, 2020, Biophytis announced a convertible line of €24 million from Atlas. The press release is available on the Company's website (www.biophytis.com) in the section "2020 press releases". The financing instrument allows the issuance of 960 ORNANE, at a par value of €25,000 each. The €24 million total financing can be drawn by Biophytis over the next 3 years, without obligation, through 8 successive tranches of €3 million each. The Company drew a first tranche of €3 million during April 2020, a second tranche of the same amount in July 2020, and a third tranche of €3 million in September 2020.

    After the drawing of the 4th and 5th tranches for a total of €6 million, €9 million will remain from the current instrument.

    Reminder of the main characteristics of the 2020 Atlas ORNANE contract issued

    The ORNANE don't bear interest and have a 24-month maturity from issuance. The holder of ORNANE may request at any time to convert them during their maturity period, and at that time, the Company will be able to redeem the ORNANE in cash. In case of cash redemption, the amount reimbursed will be limited to 115% of the principal.

    Number of securities and dilution (assumptions)

    As of June 14, based on 113, 854,795 outstanding shares, at the conversion on this day and a conversion price equal to 97% of the pricing period VWAP of €0.9094, dilution is reflected as follows:

    Impact on a shareholder's 1% stake in the Company's capital prior to the transactionNon dilutedDiluted
       
    Before issuing of new ORNANE1.00%0.95%
         
    Upon conversion of the ORNANE from tranches 4 &5 of Atlas: issuing of 6 597 212 additional shares0.95%0.90%

    About BIOPHYTIS

    Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on Euronext Growth (TICKER:ALBPS) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com

    Disclaimer

    This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding Biophytis' anticipated timing for its various Sarconeos (BIO101) clinical trials and expectations regarding commercialization. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company's clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please refer to the "Risk Factors" section of the Company's Annual 2020 Report available on BIOPHYTIS website (www.biophytis.com) and to the risks discussed in the Company's registration statement on Form F-1 and other reports filed with the Securities and Exchange Commission (the "SEC"). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    Biophytis Contact for Investor Relations

    Evelyne Nguyen, CFO

    Media contact

    Life Sci Advisors

    Sophie Baumont

    E:

    T: +33 6 27 74 74 49

    Investor Relations

    LifeSci Advisors, LLC

    Chris Maggos

    E:

     



    Primary Logo

    View Full Article Hide Full Article
    • This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy data
    • The Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021, subject to any COVID-19-related delays

    PARIS and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("BIOPHYTIS" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from…

    • This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy data

    • The Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021, subject to any COVID-19-related delays

    PARIS and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("BIOPHYTIS" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it has recruited the 155th participant for Part 2 of its COVA Phase 2-3 study of Sarconeos (BIO101) in patients infected with COVID-19.

    Recruitment of the 155th participant allows for the independent Data Monitoring Committee (DMC) to conduct its second interim analysis, based on safety and efficacy data, for the continuation of the trial in case of favorable results. The Company is to report the recommendations of the DMC based on its review of the second interim analysis results by the end of Q2 2021.

    The DMC previously delivered a favorable opinion in March on the safety of Sarconeos (BIO101) in COVID-19 and recommended the continuation of the study into Part 2, following the scheduled interim analysis of the 50 participants in Part 1 of the COVA study.

    Recruitment into Part 2 of the study continues to proceed in France and Brazil to complete enrollment of 310 participants, with the aim of filing for Emergency Use Authorization with the US Food and Drug Administration (FDA) and Conditional Approval with the European Medicines Agency (EMA) in Q3 2021. The final study results are expected in Q3 2021, subject to any COVID-19-related delays and the impact of the pandemic.

    Stanislas Veillet, President and CEO of BIOPHYTIS, said: "Completion of recruitment of the 155th patient is an important milestone for BIOPHYTIS as we will be able to measure the therapeutic potential of Sarconeos (BIO101) in COVID-19. We are now looking forward to the second interim analysis, and hope the DMC will recommend the continuation of our Phase 2-3 COVA trial upon favorable review of the safety and efficacy data."

    The COVA clinical program (clinicaltrials.gov identifier NCT04472728) is a global, multicenter, double-blind, placebo-controlled, group-sequential and adaptive design two-part study. This Phase 2-3 study assesses Sarconeos (BIO101) in patients aged 45 and older, hospitalized with severe respiratory manifestations of COVID-19. The 155 participants were recruited in 34 centers in 4 countries: the US, Brazil, France and Belgium.

    Part 1 of the COVA Study is a Phase 2 exploratory proof of concept study providing preliminary data on the safety, tolerability, and activity of Sarconeos (BIO101) in 50 patients with severe respiratory manifestations related to COVID-19.

    Part 2 of the COVA Study is a Phase 3 randomized study investigating the safety and efficacy of Sarconeos (BIO101) on the respiratory function of 310 COVID-19 participants, or up to 465 participants, including the 50 participants from Part 1 of the study.

    The final sample size will depend upon DMC recommendations from the second interim analysis.

    About BIOPHYTIS

    BIOPHYTIS SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19.

    Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts.

    The company's common shares are listed on Euronext Growth (TICKER:ALBPS) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com.

    Disclaimer

    This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding BIOPHYTIS' anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that BIOPHYTIS considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in participant recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company's clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to BIOPHYTIS or not currently considered material by BIOPHYTIS. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2020 Report available on BIOPHYTIS website (www.biophytis.com). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    BIOPHYTIS Contact for Investor Relations

    Evelyne Nguyen, CFO

    Media contact

    LifeSci Advisors

    Sophie Baumont/Chris Maggos

    E:  

    T: +33 6 27 74 74 49

    Investor Relations

    LifeSci Advisors, LLC

    Ligia Vela-Reid

    E:  

     



    Primary Logo

    View Full Article Hide Full Article
  2. PARIS, France and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("BIOPHYTIS" or the "company"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the approval by a very large majority of all resolutions falling within the remit of the Combined General Meeting.

    BIOPHYTIS' combined AGM took place today behind closed doors, due to the COVID-19 pandemic.

    2077 shareholders participated to the vote, holding…

    PARIS, France and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("BIOPHYTIS" or the "company"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the approval by a very large majority of all resolutions falling within the remit of the Combined General Meeting.

    BIOPHYTIS' combined AGM took place today behind closed doors, due to the COVID-19 pandemic.

    2077 shareholders participated to the vote, holding collectively 24 994 687 shares, or a quorum of 22.37% and 22.82% of the voting rights. The 31 resolutions were approved at a majority of over 80% and were comprising in particular those ratifying the unconsolidated and consolidated accounts for fiscal year 2020 and the allocation of profit & loss for the fiscal year ended December 31, 2020 as well as extraordinary resolutions.

    Stanislas Veillet, President and CEO of BIOPHYTIS, said: "I am very pleased that all the resolutions of the Combined General Meeting were approved by a very large majority. I would like to warmly thank all shareholders for their exceptional commitment that made it possible for us to hold this General Meeting and for their confidence in BIOPHYTIS by supporting at a majority of over 80% each resolution put to the vote."

    The results of the votes of the combined General Meeting will be available on BIOPHYTIS' website from May 11, 2021, under the section - Investors - General Assembly:

    https://www.biophytis.com/en/action/assemblees-generales/assemblee-generale/

    About BIOPHYTIS

    BIOPHYTIS SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19.

    Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts.

    The company's common shares are listed on Euronext Growth (TICKER:ALBPS) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com.

    Disclaimer

    This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding BIOPHYTIS' anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that BIOPHYTIS considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company's clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to BIOPHYTIS or not currently considered material by BIOPHYTIS. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2020 Report available on BIOPHYTIS website https://www.biophytis.com/. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    BIOPHYTIS Contact for Investor Relations

    Evelyne Nguyen, CFO

    Media contact

    Life Sci Advisors

    Sophie Baumont/Chris Maggos

    E:  

    T: +33 6 27 74 74 49

    Investor Relations

    LifeSci Advisors, LLC

    Ligia Vela-Reid

    E:  



    Primary Logo

    View Full Article Hide Full Article
  3. PARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, informs its shareholders that the second combined Annual General Meeting (AGM) will be held on May 10, 2021 at 5PM CET, at Sorbonne University, 4 Place Jussieu – 75005 Paris, France.

    As a result of restrictions placed on the movement and gatherings of persons due to the COVID-19 pandemic, the Company's Combined General Meeting will…

    PARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, informs its shareholders that the second combined Annual General Meeting (AGM) will be held on May 10, 2021 at 5PM CET, at Sorbonne University, 4 Place Jussieu – 75005 Paris, France.

    As a result of restrictions placed on the movement and gatherings of persons due to the COVID-19 pandemic, the Company's Combined General Meeting will be held behind closed doors without the physical presence of its shareholders, in accordance with the provisions of the French Decree no 2021-255 of March 9, 2021.

    The notice of meeting, published in the French official legal bulletin Bulletin des Annonces Légales Obligatoires (BALO) n° 52, dated March 10, 2021 reminds the agenda, that stays unchanged. This notice includes information on how to attend and vote at the General Meeting, as well as the vote bulletin.

    All of the documents regarding this combined AGM (and mostly the text of resolutions) are available to shareholders on the Company's website: www.biophytis.com, in the section Investors / General Assembly 2021: https://www.biophytis.com/en/action/assemblees-generales/assemblee-generale/.

    Shareholders are strongly encouraged to vote in advance of the shareholder meeting by postal mail, by appointing the Chairman of the meeting as your proxy or via the secure online platform VOTACCESS. On account of the possible effect of the Covid-19 pandemic on postal delivery times, it is recommended to return your voting forms as soon as practicable, or to vote via VOTACCESS. The unique proxi card is available on the Company's website.

    Please note that the voting forms should be submitted no later than:

    • For postal votes, the statutory deadlines apply:
      • May 6 (4-day deadline before the AGM) for issuing instructions to the proxy holder
      • May 7 (3-day deadline before the AGM) for appointing the proxy
    • VOTACCESS :
      • May 9 at 3pm CET

    The shareholders are invited to consult the notice of the meeting, as published on the BALO (Bulletin des Annonces Légales Obligatoires) no 52, dated April 30, 2021, and available on the Company website for more details and precisions, depending on their shares (registered or bearer shares).

    The vote of shareholders who submitted their vote via the post, email or the Internet for the first combined AGM remains valid and counted for the general meeting on the second call.

    Shareholders who did not vote by post or proxy as part of the first combined AGM will be invited to send their forms and shareholder certificates:

    • By post: CACEIS Corporate Trust, Service Assemblées Générales Centralisées - 14, rue Rouget de L'Isle - 92862 ISSY-LES-MOULINEAUX Cedex 9, or

    About BIOPHYTIS

    Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19.

    Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts.

    The company's common shares are listed on Euronext Growth (TICKER:ALBPS) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com.

    Disclaimer

    This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding Biophytis' anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company's clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company's Half Year 2020 Report available on BIOPHYTIS website (www.biophytis.com). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    Biophytis Contact for Investor Relations

    Evelyne Nguyen, CFO



    Media contact

    Life Sci Advisors

    Sophie Baumont/Chris Maggos

    E:

    T: +33 6 27 74 74 49

    Investor Relations

    LifeSci Advisors, LLC

    Ligia Vela-Reid

    E:



    Primary Logo

    View Full Article Hide Full Article
    • DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential
    • Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021

    PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it was granted a non-dilutive funding of €980,000 from the public investment bank BPI France's DeepTech program, for its MACA…

    • DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential

    • Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021

    PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it was granted a non-dilutive funding of €980,000 from the public investment bank BPI France's DeepTech program, for its MACA program of Macuneos (BIO201) in dry Age-Related Macular Degeneration (AMD).

    The DeepTech program aims to boost highly innovative and breakthrough projects emerging from fundamental research with attractive dedicated financing tools. The funding consists of a conditional advance of €600,000 and a grant of €380,000 which will complement existing financing for preclinical studies of Biophytis' MACA clinical program in treatment of dry AMD, an age-related degeneration of the macula, the central part of the retina. AMD is one of the leading causes of irreversible vision loss and blindness in people over the age of 50.

    Stanislas Veillet, President and CEO of Biophytis, said: "We are pleased with this funding award, which recognizes the potential of Biophytis' Macuneos (BIO201), which has demonstrated promising results in preclinical studies. There is still no available treatment for dry AMD and the loss of vision has a significant impact on patients' quality of life. Macuneos (BIO201) has the potential to address a major unmet medical need and we look forward to further investigating it in clinical phases."

    Biophytis plans to initiate a Phase 1 clinical trial (MACA-PK) in healthy volunteers in the second half of 2021, subject to regulatory review and approval as well as COVID-19-related delays and the impact of the pandemic on operational capabilities.

    Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. It is a plant-derived pharmaceutical-grade purified 9 cis-norbixin, or norbixin. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathies.

    Biophytis believes that the results from preclinical studies support continued investigation to whether Macuneos (BIO201) may stimulate biological resilience and protect the retina against phototoxic damage that leads to vision loss. Dry AMD is a common eye disorder among people over the age of 50 that affects central vision, impairing functions such as reading, driving, and facial recognition, and has a major impact on quality of life and the ability to live independently. There are currently no approved drugs for dry AMD. Based on estimates from publicly available information, AMD affects approximately 8.5% of the global population (ages 45 to 85) and is expected to increase over time as the population ages.

    About BIOPHYTIS

    Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19.

    Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD).

    The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on Euronext Growth (TICKER:ALBPS) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040).

    For more information visit www.biophytis.com

    Disclaimer

    This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding Biophytis' anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company's clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company's Half Year 2020 Report available on BIOPHYTIS website (www.biophytis.com). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    Biophytis Contact for Investor Relations

    Evelyne Nguyen, CFO

    Media contact

    Life Sci Advisors

    Sophie Baumont/Chris Maggos

    E:

    T: +33 6 27 74 74 49

    Investor Relations

    LifeSci Advisors, LLC

    Ligia Vela-Reid

    E:



    Primary Logo

    View Full Article Hide Full Article
View All Biophytis SA News